Recently Featured

Hantavirus risk remains low, CDC says, citing its ‘playbook’ response

May 29, 2026
Two doctors with the Centers for Disease Control and Prevention (CDC) stated on Wednesday that the risk to Americans from the hantavirus outbreak remains low, emphasizing that the agency is “engaged at every step.” This assurance comes amid growing concerns about the virus, which has been linked to severe respiratory illness and is typically transmitted…

FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma

May 28, 2026
On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor. This decision underscores the FDA’s commitment to expediting access…

BMS and Hengrui Pharma Forge $15.2B Collaboration on 13 Programs

May 28, 2026
Bristol Myers Squibb (BMS) has announced a strategic partnership with Hengrui Pharma to co-develop 13 early-stage programs across oncology, hematology, and immunology, with the collaboration potentially generating over $15.2 billion for Hengrui. This agreement encompasses four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five innovative candidates to be jointly discovered by both…

ASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Ends

May 28, 2026
As his term as President of the American Society of Gene and Cell Therapy (ASGCT) concludes, Dr. Terry Flotte emphasizes the critical focus on rare and ultra-rare diseases. Flotte, who is also Editor in Chief of Human Gene Therapy, highlights the upcoming conference in Boston as a pivotal moment for advancing access to cell and…

Ongoing Cases